PT-141

T-141, also known as Bremelanotide in its generic clinical name, represents a heavily modified synthetic derivative of alpha-melanocyte-stimulating hormone. In clinical trials, it has been examined as a potential treatment for a lack of sexual desire in both males and females. This synthetic peptide acts as an agonist for the melanocortin-4 (MC-4R) and melanocortin-1 (MC-1R) receptors.

The primary focus of PT-141 revolves around its ability to promote sexual arousal. The peptide’s mechanism involves binding primarily to the MC-4R and MC-1R, which are implicated in the regulation of sexual function.

Research suggests that PT-141’s agonistic action on melanocortin receptors extends beyond sexual arousal, with implications for its involvement in immune system stimulation. This multifaceted nature positions PT-141 as a peptide with diverse therapeutic potential.

Derived from melanotan 2 (MT-2), PT-141 inherits its lineage from synthetic melanocortins. The exploration of PT-141’s various applications underscores its significance in addressing both physiological and clinical challenges.